A decentralized organization Vitadao focused on supporting early-stage longevity research, has launched Matrix Biosciences, its first biotech firm.

This follows a nod by the community to team up with Dr. Vera Gorbunova who is the co-chair of the Aging Research Center in Rochester’s University.

The first payment of $300,000 will be provided by VitaDAO for Matrix Bio and the rest later on through the IP-NFT fractionalisation in early 2024.

The technology used by the VitaDAO-connected platform Molecule makes it possible to bring about the fractionalization of IP-NFT. Researchers can then list the projects through its marketplace.

These funds will be utilized for pre-clinical work on compounds derived from long-lived, cancer-resistant naked mole rats aiming at finding potential anti-cancer and age-related treatments.

The venture arm of Pfizer injected $ 4.1 million into VitaDAO, which is the very first Pfizer venture into DAO. So far, it has funded 19 projects such as Turn Biotechnologies and the University of Copenhagen research on the effects of medicinal drugs on aging.

This is a trend towards decentralized science known as DeSci, with the intention of sourcing research funding through crowdfunding and achieving decentralized ownership.

Also Read: Arbitrum Moves $59M Of Unclaimed Tokens To DAO Treasury